Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 140

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of venetoclax plus rituximab in adult patients with relapsed chronic lymphocytic leukemia (CLL) in Poland

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Plasma cell myeloma refractory+1

Not yet recruiting

Dose optimization study of ibrutinib drug combination in adult patients with haematological diseases

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Region Hovedstaden

Prostate cancer

Not yet recruiting

Evaluation of piflufolastat (18F) PET/CT for monitoring prostate cancer recurrence in patients with favourable intermediate‑risk localized disease after focal HIFU

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma pancreas

Not yet recruiting

Efficacy and Safety of SIL204 Combined with Standard Chemotherapy in Patients with Locally Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Chronic myeloid leukaemia

Not yet recruiting

Efficacy of asciminib in chronic phase chronic myeloid leukemia patients with T315I mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Non-small cell lung cancer

Not yet recruiting

Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Hepatocellular carcinoma

Not yet recruiting

Phase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Pancreatic neuroendocrine tumour

Not yet recruiting

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Acute lymphocytic leukaemia

Not yet recruiting

Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Breast cancer

Not yet recruiting

Radium-223 dichloride (223RaCl) with drug combination for patients with symptomatic bone metastases from breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Colorectal cancer

Not yet recruiting

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gilead Sciences Inc.

Evaluation of FG001 imaging agent in patients with oropharyngeal and oral squamous cell carcinoma undergoing transoral robotic surgery or neck dissection

Not yet recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:FG001
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.